We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

51 hedge funds and large institutions have $9.56M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

2% more funds holding

Funds holding: 50 → 51 (+1)

26% less capital invested

Capital invested by funds: $12.8M → $9.56M (-$3.28M)

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

60% less call options, than puts

Call options by funds: $395K | Put options by funds: $984K

Holders
51
Holders Change
+1
Holders Change %
+2%
% of All Funds
1.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
11
Closed
7
Calls
$395K
Puts
$984K
Net Calls
-$589K
Net Calls Change
+$345K

Top Buyers

1
UCFA
United Capital Financial Advisors
Texas
+$271K
2
GCP
GSA Capital Partners
United Kingdom
+$166K
3
Citadel Advisors
Citadel Advisors
Florida
+$72.8K
4
Renaissance Technologies
Renaissance Technologies
New York
+$69.1K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$54K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$1.18M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$390K
3
Deutsche Bank
Deutsche Bank
Germany
-$299K
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$216K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$167K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
26
Cutler Group
California
$67K +$11.3K +9 +17%
FNBT
27
FineMark National Bank & Trust
Florida
$62K – – –
Renaissance Technologies
28
Renaissance Technologies
New York
$60K +$69.1K +55 New
Deutsche Bank
29
Deutsche Bank
Germany
$59K -$299K -238 -81%
WMC
30
Westwood Management Corporation
Illinois
$55K – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$52K +$54K +43 +860%
Group One Trading
32
Group One Trading
Illinois
$51K -$43.9K -35 -43%
Invesco
33
Invesco
Georgia
$43K +$49K +39 New
UBS Group
34
UBS Group
Switzerland
$40K -$6.28K -5 -12%
AIM
35
Acrospire Investment Management
Illinois
$39K +$45.2K +36 New
Nomura Holdings
36
Nomura Holdings
Japan
$37K +$41.4K +33 New
Creative Planning
37
Creative Planning
Kansas
$32K +$17.6K +14 +93%
State Street
38
State Street
Massachusetts
$29K – – –
WSFS
39
Wilmington Savings Fund Society
Delaware
$27K – – –
First Manhattan
40
First Manhattan
New York
$19K – – –
Simplex Trading
41
Simplex Trading
Illinois
$17K +$20.1K +16 New
Morgan Stanley
42
Morgan Stanley
New York
$14K -$28.9K -23 -64%
Bank of Montreal
43
Bank of Montreal
Ontario, Canada
$14K – – –
BIM
44
BlackRock Investment Management
Delaware
$13K – – –
CLOS
45
Compagnie Lombard Odier SCmA
Switzerland
$11K – – –
WA
46
WFG Advisors
Texas
$11K +$12.6K +10 New
BA
47
BlackRock Advisors
Delaware
$10K – – –
IA
48
IFP Advisors
Florida
$2K +$2.51K +2 New
TRCT
49
Tower Research Capital (TRC)
New York
$1K -$3.77K -3 -75%
Bank of America
50
Bank of America
North Carolina
$1K – – –
1
2
3

NBSE Hedge Fund Activity: Q2 2016 in Review

51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2016, worth a combined $9.56M — down 26% from $12.8M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NBSE positions and 7 closed out — a net gain of 2 holders — while 7 added to existing stakes and 11 trimmed.

The largest buyer was United Capital Financial Advisors, opening a new position worth an estimated $271K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.18M sold.

  • 51 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2016, up from 50 in Q1 2016.
  • Funds reported $9.56M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2016, down 26% quarter-over-quarter.
  • 9 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2016 and 7 closed out, a net change of +2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2016 was United Capital Financial Advisors, an estimated $271K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2016 was Opaleye Management, an estimated $1.18M sold.

Based on aggregated 13F filings for Q2 2016.